Cefdinir: An advanced-generation, broad-spectrum oral cephalosporin

Clinical Therapeutics

Volumn 24, Issue 4, 2002, Pages 473-489

  Guay, David R P ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Beta lactam; Cefdinir; Cephalosporin

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; BETA LACTAM ANTIBIOTIC; CEFACLOR; CEFALEXIN; CEFDINIR; CEFPROZIL; CEPHALOSPORIN DERIVATIVE; FERROUS SULFATE; PENICILLIN V;

ADULT; ANTIMICROBIAL ACTIVITY; CHILD; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; DRUG SENSITIVITY; DRUG STABILITY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HUMAN; MORAXELLA CATARRHALIS; PHARMACOKINETICS; RESPIRATORY TRACT INFECTION; REVIEW; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

EID: 0036255165     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(02)85125-6     Document Type: Article

References (67)

1. FK482, a new orally active cephalosporin synthesis and biological properties
2. Morphological alterations of Staphylococcus aureus and Streptococcus pyogenes exposed to cefdinir, a new oral broad-spectrum cephalosporin
3. In vitro and in vivo antibacterial activities of CS-834, a novel oral carbapenem
4. In-vitro and in-vivo antibacterial activities of CS-834, a new oral carbapenem
5. In vitro antibacterial activity of FK041, a new orally active cephalosporin
6. The effects of quinolones on the adherence of type-1 fimbriated Escherichia coli to mannosylated agarose beads
7. Pharmacodynamics and pharmacokinetics of cefdinir, an oral extended spectrum cephalosporin
8. The in-vitro activity of cefdinir (FK482), a new oral cephalosporin
9. In vitro activity of cefdinir (FK 482, PD 134393, CI-983): A new orally active cephalosporin
10. Cefdinir (FK482), an orally administered cephalosporin in vitro activity comparison against recent clinical isolates from five medical centers and determination of MIC quality control guidelines
11. In vitro activity evaluations of cefdinir (FK482, CI-983, and PD134393). A novel orally administered cephalosporin
12. In vitro activity of cefdinir (FK482) and ten other antibiotics against gram-positive and gram-negative bacteria isolated from adult and pediatric patients
13. Pharmacokinetics of cefdinir and its transfer to dialysate in patients with chronic renal failure undergoing continuous ambulatory peritoneal dialysis
14. Comparative in vitro activity and β-lactamase stability of FK482, a new oral cephalosporin
15. Comparative in vitro activity of cefdinir (CI-983; FK-482) against staphylococci, gram-negative bacilli and respiratory tract pathogens
16. Cefdinir: In vitro activity study and effect of human serum
17. In vitro antibacterial activity of FK482, a new orally active cephalosporin
18. In vitro evaluation of cefdinir (FK482), a new oral cephalosporin with enhanced antistaphylococcal activity and β-lactamase stability
19. In vitro activity of cefdinir against respiratory pathogens isolated in Sicily with reference to beta-lactamase production
20. Susceptibility testing interpretive criteria and drug stability for cefdinir, cefetamet, and cefpodoxime against Neisseria gonorrhoeae
21. The sensitivity of clinical bacteria isolated in Scotland to the oral cephalosporin, cefdinir
22. Comparative in-vitro activity of cefdinir against multiresistant Haemophilus influenzae
23. Antimicrobial activity of three investigational oral cephalosporins (BK-218, cefdinir, and RU29246) against Legionella
24. Comparative in vitro activity of telithromycin (HMR 3647), three macrolides, amoxycillin, cefdinir and levofloxacin against gram-positive clinical isolates in Japan
25. In vitro antibacterial activity of LJC 11,036, an active metabolite of L-084, a new oral carbapenem antibiotic with potent antipneumococcal activity
26. In vitro and in vivo activities of LB 10827, a new oral cephalosporin, against respiratory pathogens
27. In vitro and in vivo antibacterial activities of L-084, a novel oral carbapenem, against causative organisms of respiratory tract infections
28. In vitro and in vivo antibacterial activity and pharmacokinetics of SC-002 and its derivative, SC-004: New oral cephalosporins
29. Synthesis and antibacterial activities of novel C(3)-aminopyrimidinyl substituted cephalosporins including against respiratory tract pathogens
30. Antistaphylococcal activity of cefdinir, a new oral third-generation cephalosporin, alone and in combination with other antibiotics, at supra- and sub-MIC levels
31. Post-antibiotic effects of cefdinir on Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus and Streptococcus pyogenes
32. Bactericidal activity and postantibiotic effect of cefdinir (CI 983, FK 482) against selected pathogens
33. Stability of cefdinir (CI-983, FK482) to extended-spectrum plasmid-mediated β-lactamases
34. Activities of β-lactam antibiotics against Escherichia coli strains producing extended-spectrum β-lactamases
35. Interaction of cefdinir with beta-lactamases
36. Interpretive criteria for disk diffusion tests using 5-microgram cefdinir disks with rapidly growing clinical isolates
37. Validation of Etest for seven antimicrobial agents using regulatory criteria for the assessment of antimicrobial susceptibility devices
38. Suction-induced blister fluid penetration of cefdinir in healthy volunteers following ascending oral doses
39. Distribution of cefdinir, a third generation cephalosporin antibiotic, in serum and pulmonary compartments
40. Pharmacokinetic study of an oral cepbalosporin, cefdinir, in hemodialysis patients
41. Comparison of cefdinir and penicillin V in the treatment of pediatric streptococcal tonsillopharyngitis
42. A study of 5-day cefdinir treatment for streptococcal pharyngitis in children
43. Comparison of cefdinir and penicillin for the treatment of pediatric streptococcal pharyngitis
44. Comparison of cefdinir and penicillin for the treatment of streptococcal pharyngitis
45. Five-day cefdinir treatment for streptococcal pharyngitis
46. Five-day twice daily cefdinir therapy for acute otitis media: Microbiologic and clinical efficacy
47. Five-day cefdinir course vs. ten-day cefprozil course for treatment of acute otitis media
48. Cefdinir versus amoxicillin/clavulanic acid in the treatment of suppurative acute otitis media in children
49. Cefdinir vs. amoxicillin/clavulanic acid in the treatment of suppurative acute otitis media in children
50. Comparative safety and efficacy of cefdinir vs. amoxicillin/clavulanate for treatment of suppurative acute otitis media in children
51. Study of use of cefdinir versus cephalexin for treatment of skin infections in pediatric patients
52. Cefdinir versus cephalexin for the treatment of skin and skin-structure infections
53. Comparative effectiveness and safety of cefdinir and amoxicillin-clavulanate in treatment of acute community-acquired bacterial sinusitis
54. Efficacy and safety of cefdinir in the treatment of maxillary sinusitis
55. Comparison of cefdinir and cefaclor in treatment of community-acquired pneumonia
56. Comparison of a 5 day regimen of cefdinir with a 10 day regimen of cefprozil for treatment of acute exacerbations of chronic bronchitis
57. A comparison of a five-day regimen of cefdinir with a seven-day regimen of loracarbef for the treatment of acute exacerbations of chronic bronchitis
58. International study comparing cefdinir and cefuroxime axetil in the treatment of patients with acute exacerbation of chronic bronchitis
59. Efficacy and safety of cefdinir in the treatment of patients with acute bronchitis
60. Impairment of cefdinir absorption by iron ion
61. Red stools and Omnicef
62. Comparison of the palatability of the oral suspension of cefdinir vs. amoxicillin/clavulanate potassium, cefprozil, and azithromycin in pediatric patients
63. Cefdinir (CI-983), a new oral amino-2-thiazolyl cephalosporin, inhibits human neutrophil myeloperoxidase in the extracellular medium but not the phagolysosome
64. In vitro activity of two new oral cephalosporins, cefixime and cefdinir (CI983), on human peripheral mononuclear and polymorphonuclear leukocyte functions
65. Cefdinir-induced modification of the susceptibility of bacteria to the antibacterial activity of human serum and polymorphonuclear neutrophils
66. Macrolides and clindamycin suppress the release of Shiga-like toxins from Escherichia coli 0157:H7 in vitro